Volume 11 Number 11/12 November/December 2010
1 December 2010. Related: Editorial.
2010
10th International Congress on Drug Therapy in HIV Infection, 7-11 November 2010, Glasgow
1 December 2010. Related: Conference reports.
Virological findings from the SARA trial ofboosted protease inhibitor monotherapy
1 December 2010. Related: Conference reports, Antiretrovirals, Treatment access, Virology.
Nevirapine exposure was not associated with hypersensitivity in patients from Malawi
1 December 2010. Related: Conference reports, Antiretrovirals, Side effects.
Estimating the number of people in a country or region with HIV who are undiagnosed and in need of ART
1 December 2010. Related: Conference reports, Antiretrovirals.
Highpreterm delivery rates associated with initiation of HAART during pregnancy at a London clinic
1 December 2010. Related: Conference reports, Pregnancy.
Minority M184V variants detected in women after receiving 3TC/FTC and LPV/r-containing regimens in pregnancy
1 December 2010. Related: Conference reports, Pregnancy, Drug resistance.
The Antiretroviral Pregnancy Registry reports no increased rate of birth defects with atazanavir exposure
1 December 2010. Related: Conference reports, Pregnancy.
Pharmacokinetics of lopinavir/ritonavir incombination with rifampicin based TB treatment in children
1 December 2010. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
Efavirenz versus nevirapine based first linetreatment in a South African cohort
1 December 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
GSK572: 24-week results in treatment-naive and raltegravir-experienced patients
1 December 2010. Related: Conference reports, Antiretrovirals.
Consensus guidelines recommend routine use of genotypic tropism testing: new focus on maraviroc as a switching option (2010)
1 December 2010. Related: Conference reports, Antiretrovirals, Guidelines.
UK studies on bone health: increasedfracture rates reported in HIV-positive people
1 December 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Muscle weakness or pain analysed as possible raltegravir side effect
1 December 2010. Related: Conference reports, Antiretrovirals, Side effects.
Adding maraviroc does not boost CD4s inrandomised trial
1 December 2010. Related: Conference reports, Antiretrovirals.
Switch to twice-daily unboosted atazanavir outdoes switch to once-daily dose
1 December 2010. Related: Conference reports, Antiretrovirals.
Small but higher rates of AIDS and non-AIDS complications with uncontrolled HIV despite CD4s over 350
1 December 2010. Related: Conference reports, Antiretrovirals.
12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, 4-6 November 2010, London
1 December 2010. Related: Conference reports, Lipodystrophy and metabolic complications.
Bio-Alcamid associated with unacceptable risk of complications: no longer recommended as a treatment for facial lipoatrophy
1 December 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
First International Workshop on HIV and Ageing, 4-5 October 2010, Baltimore
1 December 2010. Related: Conference reports.
T-cell senescence linked to KS in peoplewith good HIV control
1 December 2010. Related: Conference reports, Cancer and HIV, Basic science and immunology.
Higher risk of potential drug-drug interactions in HIV patients over 60
1 December 2010. Related: Conference reports, PK and drug interactions.
Age raises fracture risk more in HIV-positive people
1 December 2010. Related: Conference reports, Lipodystrophy and metabolic complications.
Shortfall in funding for the Global Fund
1 December 2010. Related: Treatment access.
FDA approval of generic ARVs
1 December 2010. Related: Treatment access.
Europe! HANDS OFF OUR MEDICINE
1 December 2010. Related: Treatment access.
DNP+ president uses 5ml of blood to meet Carla Bruni-Sarkozy
1 December 2010. Related: Treatment access.
Medicines Patent Pool: first research funder announced
1 December 2010. Related: Treatment access.
Once-daily raltegravir fails to demonstrate non-inferiority compared to twice-dailydosing in phase 3 treatment naive study
1 December 2010. Related: Antiretrovirals.
FDA safety updates to antiretroviral labels
1 December 2010. Related: Antiretrovirals, Side effects.
Update to US saquinavir label
1 December 2010. Related: Antiretrovirals, Side effects.
Pre-exposure prophylaxis (PrEP) with tenofovir/FTC reduces sexual transmission of HIV between men at high risk: results from the iPrEx study
1 December 2010. Related: HIV prevention and transmission.
FDA approves tesamorelin for reduction of central fat accumulation
1 December 2010. Related: Side effects, Lipodystrophy and metabolic complications.
Initiating nevirapine with fixed dose combination mini-pills in Zambia
1 December 2010. Related: Paediatric care.
HIV: an agenda for action
1 December 2010. Related: BHIVA news.
Berlin man remains free of detectable HIV 3.5 years after CCR5-negative stem celltransplant
1 December 2010. Related: Basic science and immunology.
Natural immunity to HIV infection
1 December 2010. Related: Basic science and immunology.
Scant embers of infection can reignite viralreplication
1 December 2010. Related: Basic science and immunology.
Evidence for sporadic low-level HIV replication on ART
1 December 2010. Related: Basic science and immunology.
Plumbing HIV pathogenesis in the gut
1 December 2010. Related: Basic science and immunology.
Genetic analyses reveal key mechanism of HIV control
1 December 2010. Related: Basic science and immunology.
Conference reports and online abstracts
1 December 2010. Related: On the web.
Online journal access
1 December 2010. Related: On the web.
Community resources and publications
1 December 2010. Related: On the web.
Volume 11 Number 11/12 November/December 2010 PDF
1 December 2010. Related: PDFs.
BHIVA monitoring guidelines online for comment (2010)
10 October 2010. Related: Guidelines.
50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12-15 September 2010, Boston
1 October 2010. Related: Conference reports.
Raltegravir pharmacokinetics inpregnancy
1 October 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Low birth weight associated with HAART in pregnancy in Zambia
1 October 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Bilirubin levels in infants following in utero atazanavir exposure compared to exposure to other antiretrovirals
1 October 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Novel mutations and shifting susceptibility to darunavir and tipranavir
1 October 2010. Related: Conference reports, Antiretrovirals, Drug resistance.
Four-drug single-pill antiretroviral equivalent to Atripla at 48 weeks
1 October 2010. Related: Conference reports, Antiretrovirals.
High rates of bone loss and progression with HIV in longitudinal study
1 October 2010. Related: Conference reports, Antiretrovirals, Side effects.
XVIII International AIDS Conference: 18-23 July 2010, Vienna
1 October 2010. Related: Conference reports.
Spray-dried nanoparticle formulation of efavirenz
1 October 2010. Related: Conference reports, Antiretrovirals.
Switching boosted-PIs to raltegravir
1 October 2010. Related: Conference reports, Antiretrovirals, Treatment strategies.
Scaling up: what to do first?
1 October 2010. Related: Conference reports, Treatment strategies, Guidelines.
A new point of care CD4 test
1 October 2010. Related: Conference reports, Basic science and immunology.
Early infant diagnosis
1 October 2010. Related: Conference reports, Antiretrovirals, Paediatric care, Diagnostics.
Efavirenz-based regimens among womenof reproductive age receiving ART in Johannesburg
1 October 2010. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
Male circumcision retains effectiveness at reducing risk of HIV infection: 54 month results
1 October 2010. Related: Conference reports, HIV prevention and transmission.
Towards a cure: HIV reservoirs and strategies to control them, 16–17 July 2010, Vienna
1 October 2010. Related: Conference reports, Cure-related research.
Rapporteur summaries
1 October 2010. Related: Conference reports, Basic science and immunology.
START study given green light for full study
1 October 2010. Related: Antiretrovirals.
Saquinavir prolongation of QT interval: Rocheissue Dear Doctor letter
1 October 2010. Related: Antiretrovirals.